The CF STORM Trial


Therapeutic category
Trial status
Open to recruitment Participating Centres
Phase IV

Full title

CF STORM; A trial to assess change in respiratory function for people with cystic fibrosis on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies

For people with cystic fibrosis (pwCF), how to reduce treatment burden has been identified as the top priority research question. Daily nebulised treatments were identified by pwCF as burdensome.

The CF STORM trial will recruit pwCF age 12 years and above that have been established on Kaftrio™ therapy. They will have an equal chance of being allocated to either stop or continue their daily nebulised muco-active therapies (dornase alfa, hypertonic saline or both).

The trial is designed to provide confidence that stopping these nebulisers does not result in a significant decline in lung function over 12 months.

The trial will not involve extra visits outside of normal clinical care.
Trial Reference Number
Trial type
Recruitment target
Last edited date
CF sponsor
Alder Hey - Liverpool
CF sponsor type

Who can take part?

Top inclusion criteria
  • 1) Established on Kaftrio™ therapy for more than 3 months
  • 2) FEV1 > 40 percent predicted
  • 3) Established on daily muco-active therapies (dornase alfa (Pulmozyme™), hypertonic saline or both) for more than 3 months
  • 4) 12 years and older

Your donation will make a difference:

Select amount